quantification of tumour
free circulating tumour DNA
EXACT-dna project
EXtended Analysis of Circulating Tumour DNA
tumour-specific biomarkers
proprietary technologies
SAGA Diagnostics
distinct technologies
revolutionary form of tumour genotyping
quantification of cell
specific quantification of gene mutations
detection
analysis of ctDNA
proprietary technology
SAGA Dx’s business model
KROMA
IBSAFE
Phase
specific chromosomal rearrangements
growing global cancer liquid biopsy market
market feasibility
liquid biopsies
business opportunity
cancer management strategies
sequence variants
body fluids
European presence
patient monitoring
users’ needs
lower production costs
revenue
road map
overwhelming superiority
primary focus
significant role
isolation
sensitivity
weeks
sales of laboratory services
wide applicability
continued clinical validation
diagnostic kits
blood samples
strategy
faster turn
verified advantages
superior performance
RNA sample
time
competing methods
healthcare
patent
hand
fold improvement
days
Forbes Magazine
competitors